Last updated on November 2007

XELOX+Bevacizumab Followed by Capecitabine+Bevacizumab+Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma


Brief description of study

The purpose of this study is to determine the pathological complete response rate of addition of bevacizumab to induction therapy (xelox) and concomitant treatment (capecitabine+radiotherapy), followed by surgery.

Clinical Study Identifier: NCT00557713

Find a site near you

Start Over

ACROSS

Barcelona, Spain
5.08miles
  Connect »